WFH/X
Aug 21, 2025, 14:49
Beyond Factor Therapy: Marstacimab for Hemophilia Care
World Federation of Hemophilia (WFH) shared a post on X:
“Beyond factor therapy: Marstacimab targets TFPI to restore thrombin generation, offering an easier, effective prophylaxis for hemophilia A and B. Strong efficacy and safety in trials. Explore the data.”
Title: Marstacimab for the Treatment of Hemophilia A or B
Author: Johnny Mahlangu
Stay updated with Hemostasis Today.
-
Aug 29, 2026, 17:05What If Factor XI inhibition Could Reshape the Future of Anticoagulation – ISTH
-
Aug 29, 2026, 16:44Nipocalimab for Warm Autoimmune Hemolytic Anemia: What the FDA Approval Means
-
Aug 29, 2026, 16:17The Future of Bleeding Disorder Research is Getting Bigger – Global Hemophilia Report
-
Aug 29, 2026, 16:03Marco De Giovanni: The Platelet – Serotonin Link Behind Severe COVID-19
-
Aug 29, 2026, 16:01FDA Approves Imaavy for wAIHA – Thalassaemia International Federation
-
Aug 29, 2026, 16:00Dianne E. van der Wal: Advancing Platelet Research at ISTH 2026 in Paris
-
Aug 29, 2026, 15:55Cory Dugan: Iron Deficiency and Anemia Across the Female Life
-
Aug 29, 2026, 15:53Melina Rodriguez: FDA Approves Imaavy as First Treatment for Warm AIHA
-
Aug 29, 2026, 15:50Karen T․: Seeking a Patient Liaison to Support the Bleeding Disorders Community